| Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave M Lee, R Quinn, K Pradhan, K Fedorov, D Levitz, A Fromowitz, A Thakkar, ... Cancer Cell 40 (4), 343-345, 2022 | 40 | 2022 |
| Targeting FLT3 mutation in acute myeloid leukemia: current strategies and future directions K Fedorov, A Maiti, M Konopleva Cancers 15 (8), 2312, 2023 | 24 | 2023 |
| Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists K Fedorov, S Goel, M Kushnir, HH Billett Research and Practice in Thrombosis and Haemostasis 5 (6), e12574, 2021 | 11 | 2021 |
| Direct oral anticoagulants for prevention of recurrent thrombosis in myeloproliferative neoplasms K Fedorov, S Goel, M Kushnir, HH Billett Blood 134, 4193, 2019 | 10 | 2019 |
| A metabolically optimized, noncytotoxic low-dose weekly decitabine/venetoclax in MDS and AML D Levitz, Y Saunthararajah, K Fedorov, LC Shapiro, I Mantzaris, A Shastri, ... Clinical Cancer Research 29 (15), 2774-2780, 2023 | 9 | 2023 |
| Identifying neutrophil extracellular traps (NETs) in blood samples using peripheral smear autoanalyzers K Fedorov, M Barouqa, D Yin, M Kushnir, HH Billett, M Reyes Gil Life 13 (3), 623, 2023 | 3 | 2023 |
| A non-cytotoxic regimen using a weekly low dose decitabine and venetoclax for MDS and AML in a real world cohort D Levitz, K Fedorov, K Pradhan, LC Shapiro, A Shastri, K Gritsman, ... Blood 140 (Supplement 1), 6218-6219, 2022 | 3 | 2022 |
| Autologous stem cell transplantation in an older adult population K Fedorov, T Jain, K Pradhan, J Mustafa, A Lombardo, F Khatun, ... Haematologica 107 (9), 2261, 2022 | 2 | 2022 |
| Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax RA Kankaria, JB Jones, M Zargari, DW Alexander, H Angle, CK Sievers, ... Leukemia & Lymphoma, 1-4, 2024 | 1 | 2024 |
| Transportation Cost Is a Significant Barrier to Quality Care for Hematologic Malignancy Patients in a Minority-Rich, Socioeconomically Disadvantaged Population L Laufer, L Amaeshi, A Sisto, K Fedorov, R Mathew, D Levitz, I Mantzaris, ... Blood 142, 2350, 2023 | 1 | 2023 |
| Neutrophilic extracellular traps (NETs); A subset of smudge cells identifiable by peripheral smear autoanalyzers in the rising era of artificial intelligence M Barouqa, K Ikemura, H Billett, M Kushnir, K Fedorov, D Yin, MR Gil American Journal of Clinical Pathology 154 (Supplement_1), S10-S11, 2020 | 1 | 2020 |
| Decitabine Activity Against TP53-Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis S Biswas, ZAM Zahran, X Gu, L Cardone, AG Jain, K Fedorov, ... Blood 144, 1382, 2024 | | 2024 |
| Application of a Phenotype-Based Predictive Analytic in a Phase Ib Study of Selinexor and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia S Ball, MT Byrne, MA Fischer, FT Awan, BK Tomlinson, T Stopczynski, ... Blood 144, 6012, 2024 | | 2024 |
| Impact of Co-Mutations, Monocytic Differentiation, and Choice of Hypomethylating Agent Combined with Venetoclax on the Predictive Value of Molecular Prognostic Risk Signature … K Fedorov, S Ball, JE Denney, AR Froenlich, A Kishtagari, S Mohan, ... Blood 144, 1474, 2024 | | 2024 |
| Case report: Isolated oligometastatic disease of the prostate from a primary lung adenocarcinoma JM Kamel, S Arjani, K Fedorov, F Sapna, J Cheng, I Mantzaris Frontiers in Oncology 14, 2024 | | 2024 |
| High Dose Cyclophosphamide for the Treatment of Severe Immune Checkpoint Inhibitor Related Adverse Events T Davis, K Fedorov, PS Gregos, LC Shapiro, A Shastri, K Gritsman, ... Journal of oncology research and therapy 8 (4), 10194, 2023 | | 2023 |
| Comparison of the Prognostic Performance of European Leukemianet 2017 and 2022 Classifications in a Minority-Rich Population of Adult Patients with Acute Myeloid Leukemia K Fedorov, A Sisto, J Kamel, M Forsberg, K Pradhan, N Shah, A Shastri, ... Blood 142, 2968, 2023 | | 2023 |
| A Study Evaluating Financial Toxicity Amongst Hematologic Malignancy Patients in the Bronx L Amaeshi, A Sisto, L Laufer, K Fedorov, R Mathew, D Levitz, I Mantzaris, ... Blood 142, 7397, 2023 | | 2023 |
| P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7+ 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML I Mantzaris, M Goldfinger, D Levitz, K Fedorov, A Munoz, N Chambers, ... HemaSphere 7 (S3), e46119b8, 2023 | | 2023 |
| P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA K Fedorov, E Feldman, Y Saunthararajah, A Shastri, N Kornblum, A Sica, ... HemaSphere 7 (S3), e90768e2, 2023 | | 2023 |
